Target intelligence / Profile preview

Alpha-6 beta-2 nicotinic acetylcholine receptor (α6β2* nAChR)

Target
α6β2* nAChR
Molecular classification
Ion channel, Ligand-gated ion channel, Nicotinic acetylcholine receptor, Receptor
01

Overview

The alpha-6 beta-2 nicotinic acetylcholine receptor (α6β2* nAChR) is a specialized subtype of pentameric ligand-gated ion channel primarily localized within the catecholaminergic nuclei of the brain, including the substantia nigra and ventral tegmental area (UniProt Consortium, 2024, 'CHRNA6 - Neuronal acetylcholine receptor subunit alpha-6'). These receptors play a pivotal role in the presynaptic regulation of dopamine release in the striatum, making them essential components of the neural circuits governing motor control and reward processing (Quik et al., 2011, 'Alpha6-containing nicotinic receptors: a target for Parkinson's disease?'). The asterisk in its nomenclature indicates that these receptors often co-assemble with other subunits, such as the beta-3 or alpha-4 subunits, to form functional complexes. Due to their restricted expression pattern, α6β2* receptors are considered high-priority therapeutic targets for Parkinson's disease, as their selective loss is a hallmark of dopaminergic neurodegeneration. Furthermore, they are heavily implicated in the reinforcing properties of nicotine, suggesting that selective ligands could provide more effective treatments for nicotine addiction with fewer side effects than non-selective agonists (PubMed, 2023, 'Targeting alpha6-containing nicotinic receptors for tobacco cessation'). Pharmacological strategies currently focus on developing potent partial agonists or antagonists that can modulate dopamine levels without triggering the widespread off-target effects associated with broader nicotinic receptor activation.

Other names
Alpha6-beta2 nicotinic receptorCHRNA6-CHRNB2 receptorAlpha6-containing nicotinic acetylcholine receptorα6β2-containing nAChR
02

Mechanism of action

The receptor acts as a pentameric ligand-gated ion channel that, upon binding of acetylcholine or nicotine, undergoes a conformational change to open a cation-selective pore, leading to depolarization and the modulation of neurotransmitter release, particularly dopamine in the striatum (Gotti et al., 2010, 'Nicotinic acetylcholine receptors: a complex family of ligand-gated ion channels with different roles in the CNS').

03

Biological functions

Dopamine release regulationNeurotransmissionSynaptic plasticitySignal transductionCation transport
04

Disease associations

Parkinson's diseaseNicotine addictionSubstance abuseNeurodegenerative disease
05

Safety considerations

Off-target effects on α3β4 receptors leading to cardiovascular toxicityGastrointestinal distress and nauseaPotential for mood alterations or psychiatric side effectsDifficulty in achieving subtype selectivity over α4β2 receptors
06

Interacting drugs

Nicotine

6 more in the full profile.

07

Biomarkers

Striatal dopamine transporter (DAT) levelsAlpha6 subunit mRNA expression in substantia nigra[18F]nifene PET imaging (general beta2 marker)Alpha6-selective radioligands

Beyond the preview

Go deeper on Alpha-6 beta-2 nicotinic acetylcholine receptor (α6β2* nAChR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-6 beta-2 nicotinic acetylcholine receptor (α6β2* nAChR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call